share_log

四環醫藥：截至二零二三年十二月三十一日止年度的全年業績公告

SIHUAN PHARM: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 28 12:17
Summary by Futu AI
四環醫藥控股集團有限公司公布截至2023年12月31日止年度全年業績，總收益約為人民幣1,860.5百萬元，較去年同期下降14.7%。醫美產品收益顯著增長200.3%，達人民幣449.9百萬元，主要得益於疫情管控放開及消費需求回暖。仿製藥收益則下降29.0%，至人民幣1,398.8百萬元，受集採降價及監控目錄影響。創新藥及其他藥品收益大幅下降80.6%，至人民幣11.8百萬元，因部分原料藥公司剝離所致。毛利率略有提升至69.6%，研發開支下降38.3%，至人民幣577.7百萬元。經營溢利為人民幣161.7百萬元，去年同期為虧損。財務開支增加至人民幣269.3百萬元，所得稅開支減少至人民幣96.4百萬元。全年虧損約為人民幣257.7百萬元，較去年大幅減少。公司擁有人應佔虧損為人民幣54.0百萬元，非控股權益應佔虧損為人民幣203.7百萬元。董事會不建議派發末期股息。
四環醫藥控股集團有限公司公布截至2023年12月31日止年度全年業績，總收益約為人民幣1,860.5百萬元，較去年同期下降14.7%。醫美產品收益顯著增長200.3%，達人民幣449.9百萬元，主要得益於疫情管控放開及消費需求回暖。仿製藥收益則下降29.0%，至人民幣1,398.8百萬元，受集採降價及監控目錄影響。創新藥及其他藥品收益大幅下降80.6%，至人民幣11.8百萬元，因部分原料藥公司剝離所致。毛利率略有提升至69.6%，研發開支下降38.3%，至人民幣577.7百萬元。經營溢利為人民幣161.7百萬元，去年同期為虧損。財務開支增加至人民幣269.3百萬元，所得稅開支減少至人民幣96.4百萬元。全年虧損約為人民幣257.7百萬元，較去年大幅減少。公司擁有人應佔虧損為人民幣54.0百萬元，非控股權益應佔虧損為人民幣203.7百萬元。董事會不建議派發末期股息。
Four Circle Pharmaceutical Holdings Group Limited announced its annual results for the year ended 31 December 2023 with total revenue of approximately RMB1,860.5 million, down 14.7% from the same period last year. Medical and cosmetic product revenue grew by a remarkable 200.3% to RMB449.9 million, mainly driven by pandemic control liberalization and warming consumer demand. Pharmaceutical revenue fell 29.0% to RMB1,398.8 million, impacted by lower collection prices and monitoring catalogs. Revenue from innovative pharmaceuticals and other pharmaceuticals fell sharply by 80.6% to RMB11.8 million, driven by the shedding of some raw material pharmaceutical companies. Gross profit rose slightly to 69.6% and R&D expenses decreased 38.3% to RMB577.7 million. Operating profit was RMB161.7 million and a loss for the same period last year. Financial expenses increased to RMB269.3 million and income tax expenses decreased to RMB96.4 million. The full-year loss was about RMB257.7 million, a significant decrease from last year. Company owners accounted for a loss of RMB54.0 million and a loss of non-controlling interests of RMB203.7 million. The Board of Directors does not recommend a final dividend.
Four Circle Pharmaceutical Holdings Group Limited announced its annual results for the year ended 31 December 2023 with total revenue of approximately RMB1,860.5 million, down 14.7% from the same period last year. Medical and cosmetic product revenue grew by a remarkable 200.3% to RMB449.9 million, mainly driven by pandemic control liberalization and warming consumer demand. Pharmaceutical revenue fell 29.0% to RMB1,398.8 million, impacted by lower collection prices and monitoring catalogs. Revenue from innovative pharmaceuticals and other pharmaceuticals fell sharply by 80.6% to RMB11.8 million, driven by the shedding of some raw material pharmaceutical companies. Gross profit rose slightly to 69.6% and R&D expenses decreased 38.3% to RMB577.7 million. Operating profit was RMB161.7 million and a loss for the same period last year. Financial expenses increased to RMB269.3 million and income tax expenses decreased to RMB96.4 million. The full-year loss was about RMB257.7 million, a significant decrease from last year. Company owners accounted for a loss of RMB54.0 million and a loss of non-controlling interests of RMB203.7 million. The Board of Directors does not recommend a final dividend.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.